风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

今年很大的制药收购：强生65亿美元全现金收购Momenta

2020-08-20 MedSci原创 MedSci原创

重症肌无力FcRn抗体nipocalimab温抗体型自身免疫溶血性贫血（wAIHA）
关注

此次交易将使强生获得Momenta自身免疫性疾病药物组合，包括抗FcRn抗体nipocalimab，该药物目前正在开发用于治疗重症肌无力。

强生公司（Johnson＆Johnson，J＆J）与美国的生物技术公司Momenta已达成最终协议，将以每股52.50美元的全现金收购Momenta，总股权价值为65亿美元。该交易很可能会在今年下半年完成。

此次交易将使强生获得Momenta自身免疫性疾病药物组合，包括抗FcRn抗体nipocalimab，该药物目前正在开发用于治疗罕见的神经肌肉疾病——重症肌无力。

FcRn的作用是帮助IgG的循环再利用，从而提高血液中自身抗体的浓度。Nipocalimab通过阻断FcRn的功能，可以降低血液中致病的自身抗体含量。

 图片来源：https://seekingalpha.com/article/4276132-rigel-competitors-collaborators

Nipocalimab的2期研究证明了其在重症肌无力患者中的疗效和耐受性。该药物还在2/3期研究中进行评估，以治疗温抗体型自身免疫溶血性贫血（wAIHA）。nipocalimab治疗wAIHA最近已经获得了FDA授予的罕见儿科疾病称号、快速通道指定和孤儿药称号。

根据强生公司的说法，Nipocalimab未来销售额将超过10亿美元。

原始出处：

http://www.pmlive.com/pharma_news/j_and_j_inks_$6.5bn_all-cash_deal_to_acquire_momenta_1347102

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=814234, encodeId=b45c8142347a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:48:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271735, encodeId=ca8012e1735db, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Aug 22 13:15:24 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811592, encodeId=a6d881159264, content=为人类健康共同努力。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Aug 20 22:40:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811591, encodeId=a4618115917d, content=巨头, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKM5opSMdO81JdZ2M7o9npdRIaB2cqAxzEC1Q9Hqht0VPJlxnQMx1IhAYibaFXYKg7emtfR6hkpZtA/132, createdBy=96432493356, createdName=yhthzx, createdTime=Thu Aug 20 22:38:30 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=814234, encodeId=b45c8142347a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:48:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271735, encodeId=ca8012e1735db, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Aug 22 13:15:24 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811592, encodeId=a6d881159264, content=为人类健康共同努力。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Aug 20 22:40:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811591, encodeId=a4618115917d, content=巨头, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKM5opSMdO81JdZ2M7o9npdRIaB2cqAxzEC1Q9Hqht0VPJlxnQMx1IhAYibaFXYKg7emtfR6hkpZtA/132, createdBy=96432493356, createdName=yhthzx, createdTime=Thu Aug 20 22:38:30 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
    2020-08-22 liuyong2980

    #强生#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=814234, encodeId=b45c8142347a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:48:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271735, encodeId=ca8012e1735db, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Aug 22 13:15:24 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811592, encodeId=a6d881159264, content=为人类健康共同努力。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Aug 20 22:40:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811591, encodeId=a4618115917d, content=巨头, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKM5opSMdO81JdZ2M7o9npdRIaB2cqAxzEC1Q9Hqht0VPJlxnQMx1IhAYibaFXYKg7emtfR6hkpZtA/132, createdBy=96432493356, createdName=yhthzx, createdTime=Thu Aug 20 22:38:30 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
    2020-08-20 言西早

    为人类健康共同努力。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=814234, encodeId=b45c8142347a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 18:48:48 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271735, encodeId=ca8012e1735db, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Aug 22 13:15:24 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811592, encodeId=a6d881159264, content=为人类健康共同努力。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Aug 20 22:40:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811591, encodeId=a4618115917d, content=巨头, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKM5opSMdO81JdZ2M7o9npdRIaB2cqAxzEC1Q9Hqht0VPJlxnQMx1IhAYibaFXYKg7emtfR6hkpZtA/132, createdBy=96432493356, createdName=yhthzx, createdTime=Thu Aug 20 22:38:30 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
    2020-08-20 yhthzx

    巨头

    0

相关资讯

没有肢体乏力，怎么就重症肌无力危象了？

无肢体无力、无眼睑下垂，患者被诊断为重症肌无力，其诊断依据是什么？

抗体片段efgartigimod治疗重症肌无力：III期试验迎硕果！

Argenx公司近日公布了抗体片段efgartigimod治疗重症肌无力（gMG）的III期临床（ADAPT研究）的最新数据，结果显示，efgartigimod已达到主要终点。

JAMA Neurol：利妥昔单抗治疗新发全身性重症肌无力

利妥昔单抗治疗新发全身性重症肌无力的临床疗效显著优于常规免疫抑制剂

Anesth Analg ：ugammadex对重症肌无力患者术后肌无力危象的影响

因为重症肌无力（MG）患者术后肌无力危象和残余神经肌肉阻断剂（NMBA）可导致呼吸衰竭，因此其需要机械通气。然而，尚不清楚使用Sugammadex逆转NMBA是否能减少MG患者手术后的肌无力危象。我们利用全国住院患者数据库分析了Sugammadex与MG患者术后肌无力危象的关系。

利润低、原料缺 这些药医院短缺

这些药，医院紧缺。 ▍这些药，医院急着采购 5月20日，广东省珠海市香洲区人民医院公布《紧缺药品询价公告》。 一批药网上无法供货，所以要采购。通过公开询价、经销商报价、遴选最低价，报价后公示3个工作日，要求经销商务必在公示期限后五个工作日内按询价结果及时送货。清单如下

AAN：Immunovant宣布其用于治疗重症肌无力的抗FcRn单抗IMVT-1401，在健康受试者中耐受良好

2019年美国神经病学学会（AAN）年会上，生物制药公司Immunovant宣布其IMVT-1401在健康受试者中的详细研究结果。